Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1232874 10.3389/fphar.2023.1232874 Pharmacology Correction Corrigendum: Essential role of microglia in the fast antidepressant action of ketamine and hypidone hydrochloride (YL-0919) Chang et al. 10.3389/fphar.2023.1232874 Chang Hai-Xia 1 2 † Dai Wei 3 † Bao Jin-Hao 2 Li Jin-Feng 2 Zhang Ji-Guo 1 * Li Yun-Feng 2 3 * 1 College of Pharmacy, Shandong First Medical University and Shandong Academy of Medical Sciences, Taian, China 2 Beijing Institute of Basic Medical Sciences, Beijing, China 3 State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratories of Neuropsychopharmacology, Institute of Pharmacology and Toxicology, Beijing, China

Edited and reviewed by: Jose Javier Miguel-Hidalgo, University of Mississippi Medical Center, United States

 *Correspondence: Ji-Guo Zhang, jgzhang@sdfmu.edu.cn; Yun-Feng Li, lyf619@aliyun.com

These authors have contributed equally to this work

 14 06 2023 2023 14 1232874 01 06 2023 09 06 2023 Copyright © 2023 Chang, Dai, Bao, Li, Zhang and Li. 2023 Chang, Dai, Bao, Li, Zhang and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Essential role of microglia in the fast antidepressant action of ketamine and hypidone hydrochloride (YL-0919) by Chang H-X, Dai W, Bao J-H, Li J-F, Zhang J-G and Li Y-F (2023). Front. Pharmacol. 14:1122541. doi: 10.3389/fphar.2023.1122541 microglia fast antidepressant action ketamine YL-0919 synaptic proteins section-at-acceptance Neuropharmacology

In the published article, there was an error in Figure 1I as published. The SEM bars of Figure 1I were not shown, and Figure 1I was revised. The corrected Figure 1 and its caption appear below.

Schematic diagram illustrating the effects of PLX5622 on rapid antidepressant action of ketamine (A); Effects of PLX5622 on behavioral tests including locomotor activity (B), immobility duration in FST (C) and latency to feed (D) in ketamine-treated mice. veh + control vs. veh + ketamine, *p < 0.05; veh + ketamine vs. PLX5622+ketamine, # p < 0.05, ## p < 0.01, n = 9–10. Schematic diagram illustrating the effects of PLX5622 on rapid antidepressant action of YL-0919 (E); Effects of PLX5622 on behavioral tests including locomotor activity (F), immobility duration in TST (G) and FST (H); and latency to feed (I) in YL-0919-treated mice, veh + control vs. veh + YL-0919, *p < 0.05, **p < 0.01; veh + YL-0919 vs. PLX5622+YL-0919, # p < 0.05, ## p < 0.01; Means ± SEM, n = 11–12.

In the published article, there was an error. The related description needs to be adjusted.

A correction has been made to Abstract, “Results,” paragraph number 01.

This sentence previously stated:

“In addition, the immobility time in TST and FST as well as latency to feed in NSFT were reduced 24 h after the intragastric (i.g.) administration of YL-0919 (2.5 mg/kg), and the rapid antidepressant effect of YL-0919 was also blocked by the microglial depletion using PLX5622.”

The corrected sentence appears below:

“In addition, the immobility time in TST and FST as well as latency to feed in NSFT were reduced 24 h after the intragastric (i.g.) administration of YL-0919 (2.5 mg/kg, administered for 5–6 consecutive days), and the rapid antidepressant effect of YL-0919 was also blocked by the microglial depletion using PLX5622.”

A correction has been made to Introduction, paragraph number 04.

This sentence previously stated:

“YL-0919, a novel antidepressant compound independently developed by our institute, was tested to be a sigma-1 receptor agonist (Ren et al., 2023).”

The corrected sentence appears below:

“YL-0919, a novel antidepressant compound developed by our institute, was tested to be a sigma-1 receptor agonist (Ren et al., 2023).”

A correction has been made to Introduction, paragraph number 04.

This sentence previously stated:

“In the clinical trial (phase IIa) with 45 depressive patients, YL-0919 showed a fast antidepressant response within 1 week.”

This sentence can be deleted.

A correction has been made to Discussion, paragraph number 02.

This sentence previously stated:

“In animal models, YL-0919 (1.25–2.5 mg/kg, i.g.) produced a rapid acting antidepressant effect in chronic unpredictable stressed (CUS) rodents within 3–5 days (Chen et al., 2018; Ran et al., 2018).”

The corrected sentence appears below:

“In animal models, YL-0919 (1.25–2.5 mg/kg, i.g.) produced a rapid acting antidepressant effect in chronic unpredictable stressed (CUS) rodents within 3–5 days (Ran et al., 2018; Sun et al., 2019).”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.